The Irradiated Brain Microenvironment Supports Glioma Stemness and Survival via Astrocyte-Derived Transglutaminase 2
- PMID: 33483373
- DOI: 10.1158/0008-5472.CAN-20-1785
The Irradiated Brain Microenvironment Supports Glioma Stemness and Survival via Astrocyte-Derived Transglutaminase 2
Abstract
The tumor microenvironment plays an essential role in supporting glioma stemness and radioresistance. Following radiotherapy, recurrent gliomas form in an irradiated microenvironment. Here we report that astrocytes, when pre-irradiated, increase stemness and survival of cocultured glioma cells. Tumor-naïve brains increased reactive astrocytes in response to radiation, and mice subjected to radiation prior to implantation of glioma cells developed more aggressive tumors. Extracellular matrix derived from irradiated astrocytes were found to be a major driver of this phenotype and astrocyte-derived transglutaminase 2 (TGM2) was identified as a promoter of glioma stemness and radioresistance. TGM2 levels increased after radiation in vivo and in recurrent human glioma, and TGM2 inhibitors abrogated glioma stemness and survival. These data suggest that irradiation of the brain results in the formation of a tumor-supportive microenvironment. Therapeutic targeting of radiation-induced, astrocyte-derived extracellular matrix proteins may enhance the efficacy of standard-of-care radiotherapy by reducing stemness in glioma. SIGNIFICANCE: These findings presented here indicate that radiotherapy can result in a tumor-supportive microenvironment, the targeting of which may be necessary to overcome tumor cell therapeutic resistance and recurrence. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/81/8/2101/F1.large.jpg.
©2021 American Association for Cancer Research.
Similar articles
-
Transglutaminase 2 Inhibition Reverses Mesenchymal Transdifferentiation of Glioma Stem Cells by Regulating C/EBPβ Signaling.Cancer Res. 2017 Sep 15;77(18):4973-4984. doi: 10.1158/0008-5472.CAN-17-0388. Epub 2017 Jul 28. Cancer Res. 2017. PMID: 28754668
-
TGM2 inhibition attenuates ID1 expression in CD44-high glioma-initiating cells.Neuro Oncol. 2013 Oct;15(10):1353-65. doi: 10.1093/neuonc/not079. Epub 2013 Jul 21. Neuro Oncol. 2013. PMID: 23877317 Free PMC article.
-
Sustained radiosensitization of hypoxic glioma cells after oxygen pretreatment in an animal model of glioblastoma and in vitro models of tumor hypoxia.PLoS One. 2014 Oct 28;9(10):e111199. doi: 10.1371/journal.pone.0111199. eCollection 2014. PLoS One. 2014. PMID: 25350400 Free PMC article.
-
Radiation therapy for glioma stem cells.Adv Exp Med Biol. 2015;853:85-110. doi: 10.1007/978-3-319-16537-0_6. Adv Exp Med Biol. 2015. PMID: 25895709 Review.
-
Radioresistance of glioma stem cells: intrinsic characteristic or property of the 'microenvironment-stem cell unit'?Mol Oncol. 2011 Aug;5(4):374-86. doi: 10.1016/j.molonc.2011.05.001. Epub 2011 May 20. Mol Oncol. 2011. PMID: 21659010 Free PMC article. Review.
Cited by
-
The Role of Transglutaminase 2 in the Radioresistance of Melanoma Cells.Cells. 2022 Apr 14;11(8):1342. doi: 10.3390/cells11081342. Cells. 2022. PMID: 35456021 Free PMC article.
-
A systematic exploration of unexploited genes for oxidative stress in Parkinson's disease.NPJ Parkinsons Dis. 2024 Aug 17;10(1):160. doi: 10.1038/s41531-024-00776-1. NPJ Parkinsons Dis. 2024. PMID: 39154038 Free PMC article.
-
Blocking the MIF-CD74 axis augments radiotherapy efficacy for brain metastasis in NSCLC via synergistically promoting microglia M1 polarization.J Exp Clin Cancer Res. 2024 Apr 29;43(1):128. doi: 10.1186/s13046-024-03024-9. J Exp Clin Cancer Res. 2024. PMID: 38685050 Free PMC article.
-
Hypoxia-induced complement component 3 promotes aggressive tumor growth in the glioblastoma microenvironment.JCI Insight. 2024 Aug 22;9(19):e179854. doi: 10.1172/jci.insight.179854. JCI Insight. 2024. PMID: 39172519 Free PMC article.
-
Radiotherapy of High-Grade Gliomas: First Half of 2021 Update with Special Reference to Radiosensitization Studies.Int J Mol Sci. 2021 Aug 19;22(16):8942. doi: 10.3390/ijms22168942. Int J Mol Sci. 2021. PMID: 34445646 Free PMC article. Review.
References
-
- Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.
-
- Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer. 2010;10:319–31.
-
- Hess CF, Schaaf JC, Kortmann RD, Schabet M, Bamberg M. Malignant glioma: patterns of failure following individually tailored limited volume irradiation. Radiother Oncol. 1994;30:146–9.
-
- Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN. Cancer stem cells in glioblastoma. Genes Dev. 2015;29:1203–17.
-
- Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–60.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous
